Makers Laboratories Limited chemical segment drove Q2 profit
Key highlights
- Chemical manufacturing contributed Rs 11.1879 crore of Makers Laboratories' Rs 11.5478 crore Q2 consolidated profit before tax.
- Pharmaceuticals reported Rs 35.99 lakh of Q2 profit before tax after a Rs 1.2574 crore loss in the preceding quarter.
- Chemical manufacturing generated Rs 35.0322 crore of Q2 segment revenue, compared with Rs 13.9262 crore for pharmaceuticals.
- Consolidated net operating cash flow was Rs 13.1362 crore in the half year ended September 30, 2026.
powered by IRIS

Makers Laboratories Limited reported Rs 11.5478 crore in consolidated profit before tax for the quarter ended September 30, 2026, as chemical manufacturing generated Rs 11.1879 crore while pharmaceuticals contributed Rs 35.99 lakh. Chemical manufacturing therefore supplied 96.9% of the group’s quarterly pre-tax profit based on the reported segment results.
Know Makers Laboratories inside out
Results, valuation, peers and who's buying, in one view.
How did Makers Laboratories generate Q2 pre-tax profit?
Makers Laboratories generated its Q2 pre-tax profit primarily through chemical manufacturing, which reported Rs 11.1879 crore against Rs 35.99 lakh from pharmaceuticals. The two segment results total Rs 11.5478 crore, matching consolidated profit before tax for the quarter ended September 30, 2026.
Chemical manufacturing’s profit before tax rose from Rs 7.5523 crore in the quarter ended June 30, 2026 and Rs 2.2281 crore in the quarter ended September 30, 2025. Pharmaceuticals returned to a Rs 35.99 lakh profit after losses of Rs 1.2574 crore in the preceding quarter and Rs 93.41 lakh in the year-earlier quarter.
Consolidated profit before tax was 8.9 times the Rs 1.2940 crore reported a year earlier and increased from Rs 6.2949 crore in the June 2026 quarter. The consolidated statement recorded no exceptional item for Q2, so the reported pre-tax increase was not accompanied by a separately disclosed exceptional gain or expense.
How did Makers Laboratories' segment revenue change?
Chemical manufacturing recorded Rs 35.0322 crore of Q2 segment revenue, compared with Rs 13.9262 crore for pharmaceuticals. Chemical revenue increased from Rs 33.1219 crore in the prior quarter and Rs 21.8884 crore a year earlier, while pharmaceutical revenue rose from Rs 10.2590 crore sequentially and Rs 12.6427 crore a year earlier.
The two segment revenue figures totalled Rs 48.9584 crore, equal to consolidated total income rather than revenue from operations alone. Consolidated revenue from operations was Rs 48.2101 crore and other income was Rs 74.83 lakh, explaining the difference between the revenue-from-operations line and the segment-revenue total.
For the half year ended September 30, 2026, chemical manufacturing revenue reached Rs 68.1541 crore, compared with Rs 43.3897 crore in the corresponding prior-year half. Pharmaceutical revenue fell to Rs 24.1852 crore from Rs 26.4085 crore, meaning chemical manufacturing accounted for the reported expansion in group segment revenue over the six-month period.
What did Makers Laboratories report after tax and for shareholders?
Makers Laboratories reported Rs 8.5263 crore in consolidated profit after tax for Q2, compared with Rs 4.5964 crore in the June quarter and Rs 74.70 lakh a year earlier. The Q2 tax charge was Rs 3.0215 crore, comprising Rs 2.8675 crore of current tax, a Rs 15.86 lakh credit relating to earlier years, and Rs 31.26 lakh of deferred tax.
Profit attributable to owners of the parent was Rs 3.9497 crore, while Rs 4.5766 crore was attributable to non-controlling interests. Non-controlling interests represent the portion of a subsidiary’s profit attributable to shareholders other than the parent, and the two allocations add to the Rs 8.5263 crore consolidated profit after tax.
Basic and diluted earnings per share, not annualised, were Rs 6.69 in Q2, against Rs 2.55 in the preceding quarter and a loss per share of Rs 0.20 a year earlier. Other comprehensive loss after tax was Rs 9.03 lakh, leaving total comprehensive income of Rs 8.4360 crore, compared with Rs 68.71 lakh in the September 2025 quarter.
Got a follow-up? Ask IRIS
What do segment assets and cash flow show?
Chemical manufacturing held Rs 127.5701 crore of segment assets at September 30, 2026, compared with Rs 115.2105 crore at June 30, 2026 and Rs 104.4799 crore a year earlier. Pharmaceutical segment assets stood at Rs 54.1470 crore, versus Rs 51.2441 crore in the preceding quarter and Rs 52.3202 crore in the year-earlier period.
Segment liabilities were Rs 24.2337 crore for chemical manufacturing and Rs 22.5769 crore for pharmaceuticals at September 30, 2026. Chemical manufacturing liabilities were below Rs 25.0395 crore at March 31, 2026, whereas pharmaceutical liabilities increased from Rs 19.1032 crore; the filing does not provide segment-level cash-flow data.
At the consolidated level, net cash from operating activities was Rs 13.1362 crore for the half year ended September 30, 2026, up from Rs 3.1245 crore in the corresponding prior-year half. Investing activities used Rs 10.1165 crore, including Rs 8.4823 crore for mutual-fund purchases, while financing activities used Rs 2.9055 crore; cash and cash equivalents ended the half at Rs 31.11 lakh, compared with Rs 91.72 lakh a year earlier.
How did first-half segment profit compare?
Chemical manufacturing produced Rs 18.7402 crore of profit before tax in the half year ended September 30, 2026, while pharmaceuticals reported a Rs 89.75 lakh loss. The chemical segment’s first-half profit was up from Rs 4.5039 crore a year earlier, whereas the pharmaceutical loss narrowed from Rs 1.2336 crore.
Group profit before tax for the half year was Rs 17.8427 crore, compared with Rs 3.2703 crore in the prior-year half. The chemical segment’s half-year result exceeded group profit because the pharmaceutical segment remained loss-making over the six months despite returning to a Q2 profit.
The consolidated financial results were approved by the board on November 4, 2026, and the statutory auditors issued an unmodified limited review report. The reported results classify the group into two reportable segments, pharmaceuticals and chemical manufacturing, under Indian Accounting Standard 108 on operating segments.
Conclusion
Makers Laboratories’ Q2 earnings increase was concentrated in chemical manufacturing, which generated Rs 11.1879 crore of the group’s Rs 11.5478 crore consolidated profit before tax. Pharmaceuticals made a Rs 35.99 lakh quarterly profit, but its Rs 89.75 lakh first-half loss shows that the group’s six-month profitability remained dependent on the chemical segment.
The unresolved operating issue disclosed by the results is whether pharmaceuticals can sustain quarterly profitability after its first-half loss, while chemical manufacturing maintains its higher revenue and profit contribution. Later segment disclosures will also show how the Rs 127.5701 crore chemical asset base and Rs 54.1470 crore pharmaceutical asset base translate into profit and cash generation.


